By Drug Target Review2025-10-10T13:30:37
Scientists have developed a new gene therapy that reversed symptoms of SYNGAP1-related brain disorders in mice, which could lead to new treatments for this group of neurological conditions.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2026-03-27T13:06:00Z
2026-03-11T14:00:00
Sponsored by Merck
2023-03-23T14:46:21
Sponsored by Bio-Techne
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2023-09-27T13:56:39
Sponsored by Euretos
2023-09-06T16:55:04
Sponsored by NanoTemper Technologies
2025-04-22T14:58:00
Sponsored by Takara Bio USA
Site powered by Webvision Cloud